Theratechnologies Inc. (NASDAQ:THTX) Q1 2022 Earnings Conference Call April 13, 2022 8:30 AM ET

Company Participants

Paul Levesque - President & CEO

Philippe Dubuc - SVP & CFO

Christian Marsolais - SVP & Chief Medical Officer

John Mullaly - IR, LifeSci Advisors

Conference Call Participants

Andre Uddin - Mackie Research Capital

Stephen Kwai - National Bank Financial

Operator

Good morning, ladies and gentlemen, and thank you for standing by. Welcome to Theratechnologies First Quarter Fiscal Year 2022 Earnings Conference Call. [Operator Instructions].

I would like to remind everyone that this conference call is being recorded today, Wednesday April 13, 2022, at 8:30 a.m. Eastern Time.

I will now turn the call over to John Mullaly, LifeSci Advisors. Mr. Mullaly, please go ahead.

John Mullaly

Thank you, and welcome. Mr. Paul Levesque, President and Chief Executive Officer of Theratechnologies; and Mr. Philippe Dubuc, Senior Vice President and Chief Financial Officer, will be the speakers on today's call. Additionally, Theratechnologies has also asked Christian Marsolais, Chief Medical Officer, to participate on today’s call, to provide an update in regard to the progress of TH1902, the company’s lead oncology asset.

Now, before Paul begins his remarks, I have been asked by Theratechnologies to read the following message regarding forward-looking statements. I would like to remind everyone that Theratechnologies' remarks today contain forward-looking statements about its current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements, or other future events or developments. In preparing these forward-looking statements, several assumptions were made by Theratechnologies, and there are risks that results actually obtained by the company will differ materially from those statements. As a consequence, the company cannot guarantee that any forward-looking statement will materialize, and you are cautioned not to place undue reliance on them. Theratechnologies refers current and potential investors to the forward-looking information section in its management discussion and analysis issued this morning available on Sedar at www.sedar.com or on EDGAR at www.sec.gov. Forward-looking statements represent Theratechnologies' expectations as of April 12, 2022. Except as may be required by securities law, Theratechnologies does not undertake any obligation to update any forward-looking statement whether as a result of new information, future events, or otherwise.

I would now like to turn the conference call over to Paul.

Paul Levesque

Thanks, John, and good morning to everyone joining the call today. We are well into the new reporting year and off to a great and solid start. As you can tell from our excitement during the year-end call, we have never been more confident in our recent history than where we are today, fully leaning into the advantages of our strategic business model consisting of both a development pipeline and a commercial drug business.